Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate

B Abrahamsen, Erik Grove, Peter Vestergaard

Research output: Contribution to journalJournal articleResearchpeer-review

66 Citations (Scopus)

Abstract

National registers showed that a large proportion of patients treated with strontium ranelate have conditions that may now contraindicate use. The risk of death in strontium ranelate-treated patients was significantly higher than that seen in users of other osteoporosis drugs even after adjusting for cardiovascular risk factor profile.
Original languageEnglish
JournalOsteoporosis International
Volume25
Issue number2
Pages (from-to)757-762
Number of pages6
ISSN0937-941X
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Dive into the research topics of 'Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate'. Together they form a unique fingerprint.

Cite this